Decision Benefits 13 Million Members, including Medicare Advantage (Cigna-HealthSpring®) participants

NEWPORT NEWS, Virginia (October 1, 2014) – Effective immediately, Cigna Healthcare, a major global health insurance company, will provide coverage for the use of TheraSkin®, a living cell therapy that effectively treats chronic wounds.

“We are pleased that Cigna has decided to cover this limb and life-saving product for their members,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin. He explained that “patients with diabetic and venous leg ulcers will now have access to the highly effective living cell therapy provided by TheraSkin. Living cell therapy has been cited as the new “gold standard” of care for these types of wounds.

Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes. “Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations.”

TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks. And TheraSkin, unlike engineered living cell products, can be used to heal particularly difficult wounds which are down to bone, tendon, muscle and joint capsules.

About 26 million Americans have diabetes today, expected to grow to 50 million by 2050. Treating diabetic foot ulcers costs the U.S. between $9-$13 billion a year. “We will work tirelessly with the medical institutions and practitioners in the CIGNA network to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.

About TheraSkin: TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.